• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » BD beats Wall Street on Q3 earnings, reveals FDA denial of Lutonix PMA for PAD

BD beats Wall Street on Q3 earnings, reveals FDA denial of Lutonix PMA for PAD

August 6, 2019 By Nancy Crotti

This article has been updated to include information from the company’s earnings call with analysts.

Becton Dickinson & Co.Becton Dickinson (NYSE:BDX) posted third-quarter results today that beat the consensus earnings forecast on Wall Street and maintained its FY2019 guidance, citing strong year-to-date results and continued momentum.

On the downside, CEO Vincent Forlenza told analysts that the FDA won’t approve the company’s Lutonix drug-coated balloon catheter for use below the knee, according to a transcript by Seeking Alpha. The agency said in March that its preliminary review of long-term follow-up data found a “potentially concerning signal” of increased long-term mortality in people with peripheral artery disease who were treated with paclitaxel-coated devices compared to those treated with bare devices.

A meta-analysis published in the Journal of the American Heart Assn. last December suggested that PAD patients treated with paclitaxel-coated balloons and stents could be at a higher risk for late death. The agency analyzed all available clinical studies conducted with the FDA-approved devices that were randomized, controlled trials or single-arm registries of at least 200 patients with at least two-year follow-up, including: the Levant 2 trial of BD’s Lutonix DCB; the RCT for Cook Medical‘s Zilver PTX DES; the In.Pact SFA I and II studies of the Medtronic (NYSE:MDT) In.Pact Admiral DCB; and the Illumenate study of the Royal Philips (NYSE:PHG) Stellarex DCB. The analysis compared drug-eluting devices with non-eluting devices.

At two years, the observed mortality rates for the paclitaxel-coated device group were higher for the Zilver PTX, Levant 2 and In.Pact SFA I & II trials, the agency said in June.

“While this determination was based on the clinical evidence provided to-date, we continue to review collaborate and align with the FDA on the path forward regarding our submission, including the need to potentially provide additional clinical data,” Forlenza told analysts. “As a result, the approval process timeline has extended out from our previous expectations and we no longer expect approval this calendar year. We will keep you informed as we work with the FDA and make further progress.

Franklin Lakes, N.J.-based BD reported profits of $413 million or $1.51 per share on sales of $4.35 billion for the three months ended June 30, 2019, sending its bottom line by 25.7% lower on sales growth of 1.7% compared with Q3 2019.

Adjusted to exclude one-time items, earnings per share were $3.08, 3¢ ahead of The Street, where analysts were looking for sales of $4.36 billion.

“Third-quarter performance was strong. Our revenues highlight the breadth and diversity of the growth drivers in our portfolio, and we are seeing strength across all three segments,” Forlenza said in a news release. “As anticipated, our performance has accelerated and we expect this momentum to continue. We remain confident in our outlook for fiscal year 2019 and our ability to deliver value to customers and shareholders.”

In the medical segment, as reported, Q3 sales of $2.311 billion increased 2.9% over the same quarter of 2018, driven by performance in the medication management and delivery solutions and pharmaceutical systems. Sales in the interventional segment increased by 2.9% over Q3 2018 to $981 million, aided by performance in the urology and critical care and surgery units.

BD maintained its earnings guidance at $11.65 to $11.75 per share for the rest of 2019 and its revenue guidance at 8% to 9% growth.

Investors reacted by sending BDX shares up 0.71% to $238.01 apiece in midday trading.

 

 

Filed Under: Blog, Business/Financial News, Featured, Food & Drug Administration (FDA), News Well, Regulatory/Compliance, Wall Street Beat Tagged With: becton dickinson, FDA

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy